Eli Lilly’s Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly’s rapid-acting insulin and need a lower-cost option, the company said Wednesday.
Lill said it’s Lispro Injection has a 50 percent lower list price than its identical medicine, Humalog U-100 (insulin lispro injection) and is available in both a vial and KwikPen. Because they are the same insulin, pharmacists will be able to substitute Insulin Lispro Injection for Humalog, the company said.
Lilly reminded that it announced plans in March, to introduce Insulin Lispro Injection, which fills another gap in the healthcare system. The people who are most likely to benefit from Insulin Lispro Injection are Medicare Part D beneficiaries, people with high-deductible health plans and the uninsured who use Humalog.
“The availability of Lilly’s Insulin Lispro Injection is important progress that helps more people afford their insulin,” said Mike Mason, senior vice president, Connected Care and Insulins. “Lilly will continue to work with health plans, wholesalers, employers and the government to work toward permanent solutions that will help every person with diabetes afford their medicines.”
“The current healthcare system isn’t working for everyone, causing a growing number of people with chronic conditions to struggle to afford their medicine,” Mason said. “But even one person with diabetes who can’t afford insulin is too many, which is why we introduced Insulin Lispro Injection. It adds to our suite of solutions that help significantly lower the amount people pay until a more sustainable solution is achieved.”